01 February 2010
Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial
Frank BoxbergerABCDEF, Heinz AlbrechtE, Peter C. KonturekE, Udo ReulbachCD, Gudrun MaennleinE, Thomas MeyerE, Werner HohenbergerE, Eckhart G. HahnE, Axel WeinABCDEFMed Sci Monit 2010; 16(2): CR49-55 :: ID: 878350
Abstract
Background
In 2003 Wein et al. published data after a short median follow up (23 months). Here we report on the long-term results.
Material and Method
The patients (n=20) received a neoadjuvant treatment regimen comprising biweekly 85 mg/m2 oxaliplatin (L-OHP) (2h-infusion, d 1, 15, 29 qd 57) and 500 mg/m2 calcium folinic acid (FA) (1-2h-infusion, d 1, 8, 15, 22, 29, 36 qd 57) followed by 2600 mg/m2 5-Fluorouracil (5-FU) (24h-infusion, d 1, 8, 15, 22, 29, 36 qd 57). Two cycles of chemotherapy were administered, with a third being added when the treatment was well tolerated. Thereafter, curative resection of the liver metastases was attempted.
Results
After neoadjuvant therapy, imaging procedures revealed complete remission in 2 patients (10%) and partial remission in 18 patients (90%). Diarrhea (Common Toxicity Criteria toxicity grade 3) was observed in 6 patients (30%) as main symptom of toxicity, followed by vomiting in 3 patients (15%). Higher grade sensomotoric neuropathy did not present. The curative resectability rate (R0) was 80%. In 9 out of 18 patients (50%) undergoing surgical intervention minor postoperative complications occurred. No postoperative mortality was observed. Over a median follow up of 45,5 months the median survival of all patients is 3.0 years and the 5-year overall survival rate is 40%. The 5-year disease-free survival rate is 25%.
Conclusions
Neoadjuvant treatment with 5-FU combined with FA and L-OHP proved to be highly effective and well tolerated. Disease-free survival rates and median overall survival rates are promising.
Keywords: Organoplatinum Compounds - therapeutic use, Neoplasm Recurrence, Local - drug therapy, Neoadjuvant Therapy, Liver Neoplasms - surgery, Leucovorin - therapeutic use, Infusion Pumps, Implantable, Fluorouracil - therapeutic use, Drug Administration Schedule, Dose-Response Relationship, Drug, Colorectal Neoplasms - pathology, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Antineoplastic Agents - therapeutic use, Patient Compliance, Time Factors
Editorial
01 September 2024 : Editorial
Editorial: Reasons for Increasing Global Concerns for the Spread of MpoxDOI: 10.12659/MSM.946343
Med Sci Monit 2024; 30:e946343
In Press
Review article
Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic PotentialMed Sci Monit In Press; DOI: 10.12659/MSM.945411
Clinical Research
Comparison of Remimazolam and Dexmedetomidine for Sedation in Awake Endotracheal Intubation in Scoliosis Su...Med Sci Monit In Press; DOI: 10.12659/MSM.944632
Database Analysis
Knowledge, Awareness, and Use of Stainless-Steel Crowns Among Dental Professionals in Sana'a City, YemenMed Sci Monit In Press; DOI: 10.12659/MSM.945948
Clinical Research
Disability Assessment with WHODAS 2.0 of People with Fibromyalgia in Poland: A Cross Sectional-StudyMed Sci Monit In Press; DOI: 10.12659/MSM.945450
Most Viewed Current Articles
17 Jan 2024 : Review article 6,053,905
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research 1,840,873
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 693,069
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
07 Jan 2022 : Meta-Analysis 257,490
Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...DOI :10.12659/MSM.935074
Med Sci Monit 2022; 28:e935074